Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 6/20 | 0.55 |
| ▸ | P2RX2 | Q9UBL9 | 6/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1099448 | 0.82 | GAA (0.55) | P2RX3P2RX2POLBGAAGFER | |
| SCHEMBL10915114 | 0.80 | PKM (0.61) | P2RX3P2RX2PKMSMN1; SMN2POLB | |
| SCHEMBL3342580 | 0.72 | PKM (0.56) | P2RX3P2RX2PKMSMN1; SMN2POLB | |
| SCHEMBL1494167 | 0.72 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL29448542 | 0.72 | P2RX3 (1.00) | P2RX3P2RX2 | |
| SCHEMBL29631745 | 0.72 | GAA (0.58) | P2RX3P2RX2PKMPOLBGAA | |
| SCHEMBL19364117 | 0.72 | GAA (0.62) | P2RX3P2RX2PKMPOLBGAA | |
| SCHEMBL16522172 | 0.72 | P2RX3 (0.81) | P2RX3P2RX2 | |
| SCHEMBL22854122 | 0.71 | ALDH1A1 (0.62) | P2RX3P2RX2SMN1; SMN2POLBGAA | |
| SCHEMBL6298412 | 0.71 | KDM4E (0.55) | P2RX3P2RX2PKMSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433258-B1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11230532-B2 | Pyrimidines and variants thereof, and uses therefor | Afferent Pharmaceuticals, Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200239421-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-10662162-B2 | Pyrimidines and variants thereof, and uses therefor | Afferent Pharmaceuticals, Inc. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190055202-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | AFFERENT PHARMACEUTICALS INC. (US) | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230532-B2 | Pyrimidines and variants thereof, and uses therefor | P2RX3, P2RX7, P2RX1 | P2RX3 1/4885P2RX2 6/4885PKM 1541/4885 |
| US-10662162-B2 | Pyrimidines and variants thereof, and uses therefor | P2RX3, P2RX7, P2RX1 | P2RX3 1/4885P2RX2 6/4885PKM 1474/4885 |
| US-20190055202-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | P2RX3, P2RX7, P2RX1 | P2RX3 1/4885P2RX2 6/4885PKM 1474/4885 |
| US-20200239421-A1 | PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR | P2RX3, P2RX7, P2RX1 | P2RX3 1/4885P2RX2 6/4885PKM 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.